Scholars Central

Conference abstractPublished 14 Apr 2022

Pharmacovigilance Systems in Latin America for COVID-19 Vaccines Brazil, Chile, Costa Rica and Mexico

Authors: Josue Bautista Arteaga

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

One of the greatest challenges to pharmacovigilance in Latin America has been the sensitivity and willingness of the population, healthcare professionals and patients, to report adverse events. As vaccination has been one of the key instruments in combatting the COVID-19 pandemic, are these pharmacovigilance systems positively influencing this sensitivity and willingness to be an active part of the surveillance of these vaccines in this public health emergency. The pharmacovigilance field in Latin-American works through four steps to examine whether the information obtained through these “real-life” (or real-world) reports is in accord with previous knowledge of these vaccines or if they present new relevant safety information that demands action: Analyze risk, understand risk, communicate risk, and mitigate risk. This article overviews the state of COVID-19 vaccinations and the systems established to analyze, understand, communicate, and mitigate their risk in Brazil Chile, Costa Rica and Mexico. e.g. Brazil. As of the end of November 2021, an estimated 300 million doses of four available vaccines had been administered in Brazil. The National Drug Monitoring Center, which was established as part of the Brazilian regulatory agency ANVISA in 2001, conducts safety surveillance of these vaccines based on five operational pillars: • Daily evaluation • Signal detection • Risk management plan • Monthly executive summary of AEs • Periodic quarterly benefit-risk assessment reports Through these and other paths of action, Brazil, Chile, Costa Rica and Mexico have adapted current structures and created new ones to communicate relevant safety information to their respective populations with transparency and robustness to ensure that the benefits of COVID-19 vaccines continue to outweigh their risks. Therefore, thanks to these innovations and updates of pharmacovigilance systems, significant improvements have been achieved that transcend in building confidence in these tools that drug science has provided us to be able to deal with a pandemic such as COVID-19.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmacology and Medicinal Chemistry
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Josue Bautista Arteaga”